Stocks Health care CGEM
NASDAQ · Health careCullinan Therapeutics, Inc. (CGEM)
It posted a net loss of $204.7M. In fiscal 2025 capital spending exceeded operating cash flow by $175.8M. At June 30, 2026 it held $78.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Cullinan Therapeutics, Inc. does
Cullinan Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CGEM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$219.9M | n/a | -$175.8M |
| 2024 | n/a | -$167.4M | n/a | -$145.3M |
| 2023 | n/a | -$153.2M | -$3.69 | -$134.5M |
| 2022 | $0 | $111.2M | $2.38 | -$127.8M |
| 2021 | $18.9M | -$65.6M | -$1.52 | -$43.4M |
| 2021 | $0 | -$51.8M | -$2.60 | -$29.8M |
Latest SEC filings
What Cullinan Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026
- September 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- June 16, 2026
- June 10, 2026
Questions about CGEM
What does Cullinan Therapeutics, Inc. do?
Cullinan Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CGEM.
Is Cullinan Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $204.7M.
When did Cullinan Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 24, 2026.
Similar companies
Follow CGEM
Get an email when Cullinan Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CGEM: get an email when it filesWhere the numbers come from
Financial figures are the values Cullinan Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.